A Novel Interaction between TFII-I and Mdm2 with a Negative Effect on TFII-I Transcriptional Activity

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

CETKOVSKÁ Kateřina ŠUSTOVÁ Hana KOSZTYU Pavlína ULDRIJAN Stjepan

Year of publication 2015
Type Article in Periodical
Magazine / Source Plos one
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1371/journal.pone.0144753
Field Genetics and molecular biology
Keywords IMMUNODEFICIENCY-VIRUS TYPE-1; WILLIAMS-BEUREN-SYNDROME; P53 TUMOR-SUPPRESSOR; LONG TERMINAL REPEAT; HISTONE DEACETYLASE-3; HUMAN CYTOMEGALOVIRUS; P53-INDEPENDENT ROLE; HIV-1 TRANSCRIPTION; ACIDIC DOMAIN; CELL-CYCLE
Description Williams-Beuren syndrome-associated transcription factor TFII-I plays a critical regulatory role in bone and neural tissue development and in immunity, in part by regulating cell proliferation in response to mitogens. Mdm2, a cellular oncogene responsible for the loss of p53 tumor suppressor activity in a significant proportion of human cancers, was identified in this study as a new binding partner for TFII-I and a negative regulator of TFII-I-mediated transcription. These findings suggest a new p53-independent mechanism by which increased Mdm2 levels found in human tumors could influence cancer cells. In addition to that, we present data indicating that TFII-I is an important cellular regulator of transcription from the immediate-early promoter of human cytomegalovirus, a promoter sequence frequently used in mammalian expression vectors, including vectors for gene therapy. Our observation that Mdm2 over-expression can decrease the ability of TFII-I to activate the CMV promoter might have implications for the efficiency of experimental gene therapy based on CMV promoter-derived vectors in cancers with Mdm2 gene amplification.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.